drugset / Trial / NCT04966325
Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
RandomizedCrossoverDouble-blindTreatment
Summary
This is a Phase 1, single-center, randomized, partially double-blind, placebo- and positive controlled, 4-way crossover study to evaluate the effect of a therapeutic and a supratherapeutic dose of LC350189 on the QTcF in healthy male and female subjects.
Timeline
- Start
- 2021-09-23
- Primary completion
- 2021-12-07
- Completion
- 2021-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Tigulixostat | Small molecule | 200 mg | Oral |
| Subject | Tigulixostat | Small molecule | 600 mg | Oral |